在结直肠癌中探索和绕过针对性治疗的耐药性
Solène Favier1, Wei Xiong2, Mounira Chalabi-Dchar2
1Université Claude Bernard Lyon 1, INSERM U-1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69008, France.
结肠直肠癌 (CRC) 疗法面临遗传和环境因素的阻力. 本综述探讨了诸如组合疗法和向持久细胞等创新策略,以克服耐药性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 分子生物学分子生物学
背景情况:
- 结肠直肠癌 (CRC) 是一个主要的全球健康问题,有针对性的疗法提供了更好的结果.
- 治疗耐药性仍然是CRC治疗的一个重大挑战,导致疾病进展.
- 耐药性机制包括遗传突变,表观遗传改变和瘤微环境 (TME) 适应.
研究的目的:
- 审查最近的突破和创新策略,以克服结直肠癌治疗耐药性.
- 突出了解瘤异质性,外体通信和TME在解决耐药性的重要性.
- 为未来的研究和临床干预提供路线图,旨在改善CRC患者的治疗结果.
主要方法:
- 关于结直肠癌研究近期进展的文献综述.
- 对针对抵抗机制的新兴策略的分析.
- 综合有关瘤生物学,信号通路和治疗方法的信息.
主要成果:
- 瘤异质性,外体介导通信和TME动态是CRC耐药性的关键因素.
- 生物标志物引导的组合疗法和表观遗传调节器在恢复治疗疗效方面显示出有前途.
- 向癌症持续细胞,细胞周期失调和DNA损伤修复 (DDR) 途径为持久反应提供了新的途径.
结论:
- 对抗性机制的全面理解对于开发有效的CRC治疗至关重要.
- 创新策略,包括组合疗法和向持久细胞,对于克服耐药性至关重要.
- 未来的研究应该专注于将这些发现转化为改善CRC患者的临床结果.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
